SANTA MONICA, Calif. & REDWOOD CITY, Calif.–(BUSINESS WIRE)– Kite, a Gilead Company (NASDAQ: GILD), and Arcellx, Inc. (NASDAQ: ACLX), today announced the closing of the companies’ previously announced global strategic collaboration to co-develop and co-commercialize Arcellx’s lead late-stage product candidate, CART-ddBCMA, for the treatment of patients with relapsed or refractory multiple myeloma. Multiple myeloma is an incurable disease for most patients and the need remains for effective, safe and broadly accessible therapies.
Kasalukuyang iniimbestigahan sa isang Phase 2 pivotal trial, ang CART-ddBCMA ay ang T-cell therapy ng Arcellx na gumagamit ng novel synthetic binder ng kumpanya, ang D-Domain. Si Kite at Arcellx ay magkasamang magsusulong at magkokomersyal ng CART-ddBCMA asset sa US, at ikokomersyal ni Kite ang produkto sa labas ng US
Therapy ng T-Cell ng CAR ay kabilang sa pambihirang paggamot para sa ilang uri ng mga kanser sa dugo. Mayroong higit sa 750 na nagpapatuloy clinical trials in CAR T-Cell therapy sa Tsina sa kasalukuyan. Maaaring makipag-ugnayan ang mga pasyenteng gustong magpatala CancerFax helpline ng pasyente sa WhatsApp + 91 96 1588 1588 o email sa info@cancerfax.com.
Tungkol kay Arcellx
Arcellx, Inc. is a clinical-stage biotechnology company reimagining cell therapy by engineering innovative immunotherapies for patients with cancer and other incurable diseases. Arcellx believes that cell therapies are one of the forward pillars of medicine and Arcellx’s mission is to advance humanity by developing cell therapies that are safer, more effective, and more broadly accessible. Arcellx’s lead product candidate, CART-ddBCMA, is being developed for the treatment of relapsed or refractory maramihang myeloma (r/r MM) in a Phase 2 pivotal trial. CART-ddBCMA has been granted Fast Track, Orphan Drug, and Regenerative Medicine Advanced Therapy designations by the U.S. Food and Drug Administration.
Arcellx is also advancing its dosable and controllable CAR-T therapy, ARC-SparX, through two programs: a Phase 1 study of ACLX-001 for r/r MM, initiated in the second quarter of 2022; and ACLX-002 in relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome, initiated in the fourth quarter of 2022.
Tungkol sa Kite
Kite, a Gilead Company, is a global biopharmaceutical company based in Santa Monica, California, focused on cell therapy to treat and potentially cure cancer. As the global cell therapy leader, Kite has treated more patients with CAR T-cell therapy than any other company. Kite has the largest in-house cell therapy manufacturing network in the world, spanning process development, vector manufacturing, clinical trial supply, and commercial product manufacturing.
Tungkol sa Agham sa Galaad
Ang Gilead Sciences, Inc. ay isang biopharmaceutical na kumpanya na naghabol at nakamit ang mga tagumpay sa medisina sa loob ng higit sa tatlong dekada, na may layuning lumikha ng isang mas malusog na mundo para sa lahat ng tao. Ang kumpanya ay nakatuon sa pagsusulong ng mga makabagong gamot upang maiwasan at gamutin ang mga sakit na nagbabanta sa buhay, kabilang ang HIV, viral hepatitis at cancer. Ang Gilead ay tumatakbo sa higit sa 35 bansa sa buong mundo, na may punong-tanggapan sa Foster City, California. Nakuha ng Gilead Sciences si Kite noong 2017.
